Select therapeutic use:
Indications for NEXIUM IV:
Short-term (up to 10 days) alternative to oral therapy for GERD with erosive esophagitis. Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy in adults.
GERD: Inject IV over ≥3 mins or infuse IV over 10–30 mins. ≥18yrs: 20–40mg once daily for ≤10 days; switch to oral form when feasible. Severe hepatic impairment: max 20mg/day. Risk reduction: initially 80mg IV over 30 mins, then 8mg/hr continuous infusion over 71.5hrs; switch to oral form when feasible. Hepatic impairment (mild-to-moderate): max continuous infusion at 6mg/hr; (severe): max 4mg/hr.
Infuse IV over 10–30 mins. <1 month: not recommended. 1 month–<1yr: 0.5mg/kg. 1yr–17yrs: <55kg: 10mg; ≥55kg: 20mg.
Symptomatic response does not preclude gastric malignancy. Discontinue if acute interstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy (eg, >3yrs) may lead to malabsorption or deficiency of Vit.B12. Use lowest dose for shortest duration appropriate to condition. Increased risk of osteoporosis-related fractures (hip, wrist, or spine) with long-term and multiple daily dose PPI therapy. Monitor magnesium levels with long-term therapy. Pregnancy. Nursing mothers.
Concomitant St. John's wort, rifampin, atazanavir, nelfinavir: not recommended. May potentiate saquinavir; monitor and consider reducing saquinavir dose. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron salts, erlotinib, digoxin). Antagonizes clopidogrel; consider alternative anti-platelets. May affect drugs metabolized by CYP2C19. May potentiate tacrolimus, cilostazol (consider reduced dose), methotrexate (consider temporary withdrawal of PPI). Caution with drugs that may cause hypomagnesemia (eg, digoxin, diuretics); monitor. Monitor warfarin. May give antacids concomitantly. May cause false (+) results in diagnostic investigations for neuroendocrine tumors; discontinue esomeprazole 14 days prior to CgA level assessment.
Proton pump inhibitor.
Headache, diarrhea, abdominal pain, nausea, flatulence, constipation, dry mouth, inj site reactions, dizziness, vertigo; rare: rash, allergic reactions, hypomagnesemia, possible C. difficile-associated diarrhea. Children: Also, somnolence, regurgitation, tachypnea, increased ALT.
See Biaxin for more information on clarithromycin. See Amoxil for more information on amoxicillin.
Hepatic (CYP2C19, CYP3A4). 97% protein bound.
Renal (primarily), fecal.
Caps (YES); Susp, IV (NO)
Caps—30, 90, 1000; Susp—30 packets/box; IV soln (single-use vial)—10